Summary
The goal of the present study was to evaluate if mibefradil, a novel nondihydropyridine Ca2+ antagonist, could block receptor-operated calcium channels (ROCC) present in human platelets and to determine the functional consequences of this blockade. Therefore, the effect of mibefradil on increases in intracellular Ca2+ concentrations and aggregation of human platelets induced by platelet activating factor (PAF) was examined. In order to differentiate effects on Ca2+ mobilization from intracellular stores from those on Ca2+ influx through ROCC, intracellular Ca2+ concentrations were measured either in fura-2-loaded platelets or in cells loaded with both BAPTA and fura-2. Mibefradil totally and dose dependently inhibited PAF-induced Ca2+ influx with a maximal effective concentration of 10 µM, but at this concentration only reduced Ca2+ mobilization from intracellular stores. A similar effect was observed when platelets were stimulated with ADP, suggesting that mibefradil was indeed interfering with ROCC and not specifically with PAF receptors. In the same range of concentrations, mibefradil inhibited Ca2+-dependent platelet aggregation induced by PAF. This effect was most likely due to the inhibition of ROCC, as Ca2+-independent aggregation induced by phorbolmyristyl-acetate (PMA) was insensitive to mibefradil. We conclude that mibefradil, which has previously been described to be an antagonist for L- and T-Type Ca2+ channels, also blocks receptor-operated Ca2+ channels. This blockade seems to be functionally relevant for platelet aggregation.
Similar content being viewed by others
References
Mishra SK, Hermsmeyer K. Selective inhibition of T-type Ca2+ channels by Ro 40-5967.Circ Res 1994;75:144–148.
Lacinova L, Welling A, Bosse E, Ruth P, Flockerzi V, Hofmann F. Interaction of Ro 40-5967 with the stable expressed alphal subunit of the cardiac L-type calcium channel. Submitted.
Clozel J-P, Osterrieder W, Kleinbloesem CH, et al. Ro 40-5967: A new nondihydropyridine calcium antagonist.Cardiovasc Drug Rev 1991;9:4–17.
Avdonin PV, Men'shikov M, Svitina UI, Tkachuk VA. Blocking of the receptor-stimulated calcium entry into human platelets by verapamil and nicardipine.Thromb Res 1988;52:587–597.
Blache D, Ciavatti M, Ojeda C. The effect of calcium channel blockers on blood platelet function, especially calcium uptake.Biochim Biophys Acta 1987;923:401–412.
Lee TC, Malone B, Snyder F. Stimulation of calcium uptake by 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (plateletactivating factor) in rabbit platelets: Possible involvement of the lipoxygenase pathway.Arch Biochem Biophys 1983;223:33–39.
Blache D, Ciavatti M, Ojeda C. Platelet aggregation and endogenous 5-HT secretion in presence of Ca2+, Sr2+ and Ba2+. Effects of calcium antagonists.Thromb Res 1987;46:779–791.
Johnsson H. Effects of nifedipine (Adalat®) on platelet function in vitro and in vivo.Thromb Res 1981;21:523–528.
MacIntyre DE, Shaw AM. Phospholipid-induced human platelet activation: Effects of calcium channel blockers and calcium chelators.Thromb Res 1983;31:833–844.
Mehta J, Mehta P, Ostrowski N, Crews F. Effects of verapamil on platelet aggregation, ATP release and thromboxane generation.Thromb Res 1983;30:469–475.
Valone FH. Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers.Thromb Res 1987;45:427–435.
Vinge E, Andersson TL, Larsson B. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.Acta Physiol Scand 1988;133:407–416.
Wade PJ, Lunt DO, Lad N, Tuffin DP, McCullagh KG. Effect of calcium and calcium antagonists on [3H]-PAF-acether binding to washed human platelets.Thromb Res 1986;41:251–262.
Pannocchia A, Praloran N, Arduino C, et al. Absence of (−)[3H]desmethoxyverapamil binding sites on human platelets and lack of evidence for voltage-dependent calcium channels.Eur J Pharmacol 1987;142:83–91.
Avdonin PV, Cheglakov IB, Boogry EM, Svitina UI, Mazaev AV, Tkachuk VA. Evidence for the receptor-operated calcium channels in human platelet plasma membrane.Thromb Res 1987;46:29–37.
Tsien RY, Pozzan T, Rink TJ. Calcium homeostasis in intact lymphocytes: Cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator.J Cell Biol 1982;94:325–334.
Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties.J Biol Chem 1985;260:3440–3450.
Gabbasov ZA, Popov EG, Gavrilov I, Pozin E. Platelet aggregation: The use of optical density fluctuations to study microaggregate formation in platelet suspension.Thromb Res 1989;54:215–223.
Avdonin PV, Cheglakov IB, Tkachuk VA. Stimulation of non-selective cation channels providing Ca2+ influx into platelets by platelet-activating factor and other aggregation inducers.Eur J Biochem 1991;198:267–273.
Hallam TJ, Rink TJ. Agonists stimulate divalent cation channels in the plasma membrane of human platelets.FEBS Lett 1985;186:175–179.
Sage SO, Rink TJ. Effects of ionic substitution on [Ca2+]1 rises evoked by thrombin and PAF in human platelets.Eur J Pharmacol 1986;128:99–107.
Davies TA, Drotts DL, Weil GJ, Simons ER. Cytoplasmic Ca2+ is necessary for thrombin-induced platelet activation.J Biol Chem 1989;264:19600–19606.
MacDougall SL, Grinstein S, Gelfand EW. Detection of ligand-activated conductive Ca2+ channels in human B lymphocytes.Cell 1988;54:229–234.
Tsien RY. New calcium indicators and buffers with high selectivity against magnesium and protons: Design, synthesis, and properties of prototype structures.Biochemistry 1980;19:2396–2404.
Motulsky HJ, Snavely MD, Hughes RJ, Insel PA. Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors.Circ Res 1983;52:226–231.
Schmitt R, Kleinbloesem CH, Belz GG. Hemodynamic and humoral effects of the novel calcium antoagonist Ro 40-5967 in patients with hypertension.Clin Pharmacol Ther 1992;52:314–323.
Portegies MCM, Schmitt R, Kraaij CJ, et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.J Cardiovasc Pharmacol 1991;18:746–751.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hahn, M., Tkachuk, V.A., Bochkov, V.N. et al. Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): Effects on intracellular calcium and platelet aggregation. Cardiovasc Drug Ther 9, 815–821 (1995). https://doi.org/10.1007/BF00879876
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00879876